DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer.

[1]  P. Jänne,et al.  Kinase drug discovery 20 years after imatinib: progress and future directions , 2021, Nature Reviews Drug Discovery.

[2]  Senlin Xu,et al.  Alternative approaches to target Myc for cancer treatment , 2021, Signal Transduction and Targeted Therapy.

[3]  K. Dalby,et al.  Development of cell‐based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA‐PKcs and OCT4–MK2 interactions , 2021, Biotechnology and bioengineering.

[4]  D. Fairlie,et al.  Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc , 2020, Molecular Cancer.

[5]  Qing Yang,et al.  The role of ubiquitination and deubiquitination in cancer metabolism , 2020, Molecular cancer.

[6]  H. Shimada,et al.  MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma , 2020, Cell Death & Disease.

[7]  M. Odero,et al.  A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia , 2020, Blood Cancer Journal.

[8]  Wei Yue,et al.  Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol. , 2019, Bio-protocol.

[9]  Min H. Kang,et al.  DNA-PK as an Emerging Therapeutic Target in Cancer , 2019, Front. Oncol..

[10]  Jeroen A. A. Demmers,et al.  Mediator complex interaction partners organize the transcriptional network that defines neural stem cells , 2019, Nature Communications.

[11]  Emily J. Girard,et al.  Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma , 2019, Nature communications.

[12]  Colin J. Daniel,et al.  Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals , 2018, Genes & development.

[13]  M. Sos,et al.  Family matters: How MYC family oncogenes impact small cell lung cancer , 2017, Cell cycle.

[14]  Pan Tong,et al.  CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. , 2017, Cancer research.

[15]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[16]  Hong Wang,et al.  Hierarchical Oct4 Binding in Concert with Primed Epigenetic Rearrangements during Somatic Cell Reprogramming. , 2016, Cell reports.

[17]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[18]  Rosalie C Sears,et al.  Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation. , 2015, Cell reports.

[19]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[20]  A. Look,et al.  Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study , 2015, British Journal of Cancer.

[21]  T. Triche,et al.  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression , 2015, Clinical Cancer Research.

[22]  Darjus F. Tschaharganeh,et al.  CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma , 2014, Genes & development.

[23]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[24]  T. Slaga,et al.  DSSylation, a novel protein modification targets proteins induced by oxidative stress, and facilitates their degradation in cells , 2014, Protein & Cell.

[25]  Herbert Waldmann,et al.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.

[26]  Patrick G. A. Pedrioli,et al.  Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages , 2012, Proceedings of the National Academy of Sciences.

[27]  O. Kallioniemi,et al.  CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes , 2012, Oncogene.

[28]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[29]  Hui-Kuan Lin,et al.  Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.

[30]  D. R. Webster,et al.  Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. , 2012, Leukemia research.

[31]  W. Vermeulen,et al.  ATP-dependent chromatin remodeling in the DNA-damage response , 2012, Epigenetics & Chromatin.

[32]  W. William,et al.  Novel strategies for the treatment of small-cell lung carcinoma , 2011, Nature Reviews Clinical Oncology.

[33]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[34]  P. Houghton,et al.  National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing , 2011, Pediatric blood & cancer.

[35]  M. Henriksson,et al.  Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation , 2009, Proceedings of the National Academy of Sciences.

[36]  S. Guan,et al.  SIRT6 stabilizes DNA-dependent Protein Kinase at chromatin for DNA double-strand break repair , 2009, Aging.

[37]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[38]  R. Lock,et al.  Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. , 2007, Blood.

[39]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[40]  S. Berger,et al.  Repression of GCN5 Histone Acetyltransferase Activity via Bromodomain-Mediated Binding and Phosphorylation by the Ku–DNA-Dependent Protein Kinase Complex , 1998, Molecular and Cellular Biology.

[41]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[42]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[43]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.